Biocept announces receipt of deficiency notice from nasdaq regarding requirement to timely quarterly report on form 10-q

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the “notice”) on august 17, 2022 from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) advising biocept that it was not in compliance with nasdaq's continued listing requirements under the nasdaq listing rule 5250(c)(1) (the “rule”) as a result of its failure to file its quarterly report on form 10
BIOC Ratings Summary
BIOC Quant Ranking